8-K: Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Lisata Therapeutics reports its full year 2023 financial results, highlighting the completion of enrollment in the Phase 2b ASCEND trial and reaffirming its operational funding projection into early 2026.

Summary

• Lisata Therapeutics announced its financial results for the year ended December 31, 2023, with operating expenses totaling $25.7 million, a significant decrease from $57.6 million in 2022.
• This decrease is largely due to a reduction in in-process research and development expenses related to the merger with Cend Therapeutics.
• The company's research and development expenses were $12.7 million for 2023, slightly down from $13.1 million in 2022.
• General and administrative expenses also decreased to $13.0 million in 2023 from $14.1 million in 2022.
• Lisata reported a net loss of $20.8 million for 2023, compared to a net loss of $54.2 million in 2022.
• As of December 31, 2023, Lisata had approximately $50.5 million in cash, cash equivalents, and marketable securities.
• The company projects that its current capital will fund operations into early 2026, covering all ongoing and planned clinical trials.
• The Phase 2b ASCEND trial is fully enrolled with 158 patients, and topline data from the first 98 patients is expected in the fourth quarter of 2024.
• The complete data set from the ASCEND trial is expected by mid-2025.
• Lisata is also advancing other clinical trials, including the BOLSTER trial, CENDIFOX trial, iLSTA trial, and a Phase 2a study in GBM.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with significant reductions in operating expenses, a strong cash position, and promising clinical trial results. The company's strategic partnerships and regulatory designations further enhance the positive sentiment. However, the company is still in the clinical stage and has not yet generated revenue from product sales, which introduces some risk.

Positives

• Operating expenses have significantly decreased, indicating improved financial management.
• The company has a strong cash position of $50.5 million, providing a runway into early 2026.
• The Phase 2b ASCEND trial is fully enrolled and on track for topline data in late 2024.
• LSTA1 has shown promising results in early clinical trials, including improved survival rates in pancreatic cancer.
• The company has secured orphan drug and fast track designations, which can expedite the regulatory process.
• Lisata has established strategic partnerships, including with Qilu Pharmaceutical in China, which can provide additional funding and resources.
• The company has a diverse clinical development portfolio with multiple ongoing trials in various solid tumor types.
• LSTA1 has demonstrated a strong scientific foundation with numerous publications supporting its efficacy.

Negatives

• The company reported a net loss of $20.8 million for 2023, although this is a significant improvement from the $54.2 million loss in 2022.
• The company is still in the clinical stage and has not yet generated revenue from product sales.
• The company is dependent on the success of its clinical trials and regulatory approvals for future growth.
• The company has a history of losses and may require additional capital in the future.

Risks

• Clinical trial results may not be positive, which could impact the company's ability to obtain regulatory approvals.
• Regulatory approvals may be delayed or not granted, which could impact the company's ability to commercialize its products.
• The company may face competition from other pharmaceutical companies developing similar therapies.
• The company may need to raise additional capital in the future, which could dilute existing shareholders.
• The company's financial projections are based on certain assumptions, which may not materialize.
• The company is subject to risks associated with the pharmaceutical industry, including product liability and intellectual property risks.

Future Outlook

Lisata projects that its current capital will fund operations into early 2026, encompassing anticipated data milestones from all its ongoing and planned clinical trials. The company expects numerous data announcements in the coming 12 to 24 months, including topline data from the Phase 2b ASCEND trial in the fourth quarter of 2024.

Management Comments

• 2023 was a testament to our unwavering commitment to operational excellence and focused, efficient development.
• Our entire organization worked seamlessly to achieve significant milestones in the advancement of our lead investigational product, LSTA1.
• Throughout 2024, we look to maintain and even build on this momentum as we project numerous data announcements in the coming 12 to 24 months.
• Our prudent stewardship of our financial resources allows us to reaffirm our projection that our cash runway extends into early 2026 and funds all our trials until data completion.
• More than ever, we remain confident in our ability to execute our development activities efficiently with the goal of reaching significant clinical milestones at the earliest possible juncture.

Industry Context

Lisata's focus on improving drug delivery to solid tumors addresses a significant unmet need in cancer treatment. The company's CendR technology and LSTA1 product candidate are positioned to potentially enhance the efficacy of existing and emerging anti-cancer therapies. The company's partnerships and clinical trial collaborations reflect a broader trend in the pharmaceutical industry towards collaborative drug development and combination therapies.

Comparison to Industry Standards

• The reported 55% improvement in median overall survival and 76% improvement in median progression-free survival in the Phase 1b/2a trial of LSTA1 in combination with gemcitabine and nab-paclitaxel for pancreatic cancer is a significant improvement compared to the standard of care alone. For example, the standard of care gemcitabine and nab-paclitaxel combination has shown a median overall survival of approximately 8.5 months and a median progression-free survival of 5.5 months in the pivotal trial by Von Hoff et al. in the New England Journal of Medicine.
• The company's cash runway into early 2026 is a positive sign, as many clinical-stage biotech companies face challenges in securing funding for their development programs. This is comparable to other companies in the sector that have successfully raised capital to fund their clinical trials.
• The orphan drug and fast track designations for LSTA1 are also positive, as they can provide regulatory advantages and potentially accelerate the approval process. These designations are common for companies developing treatments for rare diseases or conditions with unmet medical needs.
• The company's strategic partnership with Qilu Pharmaceutical is similar to other biotech companies that seek to expand their reach and commercialization potential through collaborations with regional partners. This is a common strategy for companies looking to enter the Chinese market.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial position and promising clinical trial results.
• Employees will benefit from the company's continued growth and development.
• Patients with advanced solid tumors may benefit from the development of new and effective therapies.
• The company's partnerships and collaborations will benefit its partners and collaborators.
• The company's success will benefit the broader scientific and medical community.

Next Steps

• Lisata will continue to advance its clinical trials, including the Phase 2b ASCEND trial, the BOLSTER trial, the CENDIFOX trial, the iLSTA trial, and the Phase 2a study in GBM.
• The company expects to release topline data from the Phase 2b ASCEND trial in the fourth quarter of 2024.
• Lisata will continue to explore conditional approvals in several jurisdictions around the world and/or to design an optimized Phase 3 program in pancreatic ductal adenocarcinoma.
• The company will continue to advance its other active and planned studies investigating LSTA1 in combination with a variety of standard-of-care regimens across multiple solid tumor indications.

Key Dates

Keywords

LSTA1, cancer therapy, clinical trials, pancreatic cancer, solid tumors, drug development, CendR, orphan drug, pharmaceutical, biotechnology